Winfred Woodrow Williams, Jr., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 33 | 2024 | 4262 | 1.560 |
Why?
|
| Cold Ischemia | 1 | 2023 | 72 | 0.810 |
Why?
|
| Organ Preservation | 2 | 2023 | 393 | 0.790 |
Why?
|
| Kidney Failure, Chronic | 9 | 2020 | 2496 | 0.690 |
Why?
|
| Organ Transplantation | 3 | 2023 | 1176 | 0.600 |
Why?
|
| Medicine | 3 | 2024 | 945 | 0.580 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2022 | 529 | 0.560 |
Why?
|
| Graft Rejection | 14 | 2024 | 4492 | 0.550 |
Why?
|
| Kidney | 21 | 2021 | 7064 | 0.530 |
Why?
|
| Kidney Diseases | 5 | 2023 | 2100 | 0.520 |
Why?
|
| Hepatitis C, Chronic | 3 | 2021 | 1032 | 0.520 |
Why?
|
| Immunologic Factors | 1 | 2024 | 1596 | 0.480 |
Why?
|
| Antiviral Agents | 7 | 2021 | 3073 | 0.450 |
Why?
|
| Health Status Disparities | 2 | 2021 | 1885 | 0.420 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 2029 | 0.400 |
Why?
|
| Hepatitis C | 9 | 2021 | 1595 | 0.390 |
Why?
|
| Liver Transplantation | 5 | 2021 | 2401 | 0.380 |
Why?
|
| Apolipoproteins | 1 | 2013 | 328 | 0.370 |
Why?
|
| Diabetic Nephropathies | 3 | 2013 | 973 | 0.370 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3415 | 0.360 |
Why?
|
| Immunosuppressive Agents | 14 | 2024 | 4206 | 0.340 |
Why?
|
| Social Justice | 2 | 2024 | 486 | 0.320 |
Why?
|
| Lipoproteins, HDL | 1 | 2013 | 682 | 0.320 |
Why?
|
| Ethics, Medical | 2 | 2024 | 785 | 0.310 |
Why?
|
| Students, Medical | 1 | 2021 | 1964 | 0.290 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 1622 | 0.280 |
Why?
|
| Cyclosporine | 5 | 2004 | 777 | 0.260 |
Why?
|
| Complement C4b | 6 | 2002 | 124 | 0.260 |
Why?
|
| Hepacivirus | 4 | 2021 | 1344 | 0.240 |
Why?
|
| History of Medicine | 1 | 2024 | 42 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2013 | 3447 | 0.220 |
Why?
|
| Journalism, Medical | 1 | 2023 | 73 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 2298 | 0.210 |
Why?
|
| Graft Survival | 3 | 2012 | 3887 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 560 | 0.200 |
Why?
|
| Lupus Nephritis | 1 | 2005 | 327 | 0.200 |
Why?
|
| Aminoisobutyric Acids | 1 | 2020 | 39 | 0.180 |
Why?
|
| School Admission Criteria | 1 | 2021 | 107 | 0.170 |
Why?
|
| Ribavirin | 3 | 2015 | 395 | 0.170 |
Why?
|
| Cold Temperature | 1 | 2023 | 791 | 0.160 |
Why?
|
| Cyclopropanes | 1 | 2020 | 436 | 0.160 |
Why?
|
| Leucine | 1 | 2020 | 547 | 0.160 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 373 | 0.160 |
Why?
|
| Proline | 1 | 2020 | 455 | 0.160 |
Why?
|
| Lactams, Macrocyclic | 1 | 2020 | 319 | 0.160 |
Why?
|
| Quinoxalines | 1 | 2020 | 297 | 0.150 |
Why?
|
| Humans | 59 | 2024 | 768166 | 0.150 |
Why?
|
| Tacrolimus | 4 | 2004 | 750 | 0.150 |
Why?
|
| Interferon-alpha | 3 | 2015 | 910 | 0.140 |
Why?
|
| Cryoglobulinemia | 2 | 2015 | 84 | 0.140 |
Why?
|
| Nephrology | 1 | 2020 | 270 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2005 | 1255 | 0.130 |
Why?
|
| Perfusion | 1 | 2021 | 1401 | 0.130 |
Why?
|
| Complement C4 | 6 | 2002 | 216 | 0.130 |
Why?
|
| Mycophenolic Acid | 4 | 2003 | 348 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2020 | 864 | 0.120 |
Why?
|
| Complement Activation | 4 | 2001 | 447 | 0.120 |
Why?
|
| Elastic Modulus | 1 | 2015 | 211 | 0.120 |
Why?
|
| Schools, Medical | 1 | 2021 | 883 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1162 | 0.110 |
Why?
|
| Minority Groups | 1 | 2021 | 1216 | 0.110 |
Why?
|
| RNA, Viral | 2 | 2020 | 2872 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2013 | 313 | 0.100 |
Why?
|
| Outpatients | 1 | 2020 | 1600 | 0.100 |
Why?
|
| Ireland | 1 | 2012 | 170 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 2973 | 0.100 |
Why?
|
| History, 19th Century | 2 | 2024 | 714 | 0.090 |
Why?
|
| Erythropoietin | 2 | 2012 | 718 | 0.090 |
Why?
|
| Finland | 1 | 2012 | 609 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2020 | 1982 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 716 | 0.090 |
Why?
|
| Isoantibodies | 4 | 2009 | 681 | 0.090 |
Why?
|
| Transplantation Tolerance | 2 | 2008 | 633 | 0.080 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 4833 | 0.080 |
Why?
|
| Education, Medical | 1 | 2021 | 1742 | 0.080 |
Why?
|
| Peptide Fragments | 6 | 2002 | 5151 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 414 | 0.080 |
Why?
|
| Tissue Donors | 5 | 2021 | 2381 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2337 | 0.080 |
Why?
|
| Glomerulonephritis | 2 | 2002 | 333 | 0.080 |
Why?
|
| Nephrotic Syndrome | 2 | 2005 | 381 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 8054 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 18065 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2024 | 1573 | 0.070 |
Why?
|
| United States | 6 | 2024 | 73039 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1907 | 0.070 |
Why?
|
| Pregnancy | 3 | 2022 | 30256 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 1999 | 1134 | 0.070 |
Why?
|
| Antibodies | 4 | 2022 | 2421 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1791 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2021 | 6611 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2024 | 2766 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2021 | 3463 | 0.060 |
Why?
|
| Clinical Chemistry Tests | 1 | 2005 | 59 | 0.060 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 594 | 0.060 |
Why?
|
| Adult | 27 | 2020 | 223646 | 0.060 |
Why?
|
| Pregnancy Proteins | 1 | 2005 | 222 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 1988 | 960 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2003 | 27 | 0.050 |
Why?
|
| Ethics, Professional | 1 | 2023 | 100 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 1441 | 0.050 |
Why?
|
| Female | 27 | 2022 | 397192 | 0.050 |
Why?
|
| Scientific Misconduct | 1 | 2023 | 77 | 0.050 |
Why?
|
| Thymus Gland | 1 | 1988 | 1266 | 0.050 |
Why?
|
| Complement C3b | 2 | 1999 | 98 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 1988 | 2678 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2015 | 22291 | 0.050 |
Why?
|
| Menstruation | 1 | 2003 | 310 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2003 | 492 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2909 | 0.050 |
Why?
|
| Contraception Behavior | 1 | 2003 | 186 | 0.050 |
Why?
|
| HLA Antigens | 3 | 2001 | 1334 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 5804 | 0.050 |
Why?
|
| Male | 31 | 2020 | 364719 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 5797 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5717 | 0.050 |
Why?
|
| Prejudice | 1 | 2024 | 574 | 0.040 |
Why?
|
| Postoperative Complications | 5 | 2019 | 15832 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 812 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 2709 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2011 | 2747 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 770 | 0.040 |
Why?
|
| Kidney Tubules | 3 | 2012 | 454 | 0.040 |
Why?
|
| Premenopause | 1 | 2003 | 1039 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2001 | 246 | 0.040 |
Why?
|
| Antibody Formation | 5 | 2002 | 1393 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 62 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1999 | 105 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 2227 | 0.040 |
Why?
|
| Ischemia | 3 | 1996 | 1900 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 1999 | 104 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2013 | 12795 | 0.040 |
Why?
|
| Biopsy | 5 | 2008 | 6793 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2020 | 340 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2001 | 738 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1998 | 159 | 0.040 |
Why?
|
| Cardiolipins | 1 | 1997 | 83 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2019 | 1601 | 0.040 |
Why?
|
| Middle Aged | 24 | 2019 | 223492 | 0.030 |
Why?
|
| Renal Artery | 1 | 1999 | 354 | 0.030 |
Why?
|
| Phenanthridines | 1 | 1996 | 50 | 0.030 |
Why?
|
| Donor Selection | 1 | 2019 | 240 | 0.030 |
Why?
|
| Publishing | 1 | 2024 | 837 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2003 | 1480 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 4427 | 0.030 |
Why?
|
| Fibrosis | 2 | 2015 | 2080 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 1996 | 143 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 1997 | 232 | 0.030 |
Why?
|
| Placenta | 1 | 2005 | 1725 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1996 | 291 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2020 | 779 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 1998 | 570 | 0.030 |
Why?
|
| Acute Disease | 6 | 2003 | 7243 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1998 | 336 | 0.030 |
Why?
|
| Triazines | 1 | 1996 | 311 | 0.030 |
Why?
|
| Viremia | 1 | 1997 | 726 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 939 | 0.030 |
Why?
|
| Phenotype | 1 | 2012 | 16726 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2020 | 2089 | 0.030 |
Why?
|
| Sp3 Transcription Factor | 1 | 2013 | 30 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8741 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15948 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20227 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 10266 | 0.030 |
Why?
|
| Peroxidase | 4 | 1999 | 610 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 656 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 2171 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 13014 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 1528 | 0.030 |
Why?
|
| Informed Consent | 1 | 2019 | 1010 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2001 | 4793 | 0.020 |
Why?
|
| Massachusetts | 1 | 2024 | 8890 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 30010 | 0.020 |
Why?
|
| Maleimides | 1 | 2011 | 112 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 6514 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 6316 | 0.020 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2015 | 398 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 1999 | 1309 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1323 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1998 | 4568 | 0.020 |
Why?
|
| Acute Kidney Injury | 3 | 1999 | 1942 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 638 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2021 | 81762 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2009 | 183 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4194 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 1 | 1988 | 112 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2020 | 54926 | 0.020 |
Why?
|
| Chronic Disease | 5 | 2003 | 9384 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 892 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 1613 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 165 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1999 | 1483 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2001 | 3301 | 0.020 |
Why?
|
| Serine | 1 | 2011 | 831 | 0.020 |
Why?
|
| Creatinine | 3 | 1999 | 1918 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3591 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2011 | 1156 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2011 | 1751 | 0.020 |
Why?
|
| Aged | 7 | 2019 | 171504 | 0.020 |
Why?
|
| Capillaries | 2 | 2001 | 755 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 277 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 733 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 1047 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1382 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2002 | 2474 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2008 | 537 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 1251 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2005 | 26422 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2011 | 1530 | 0.020 |
Why?
|
| Anemia | 1 | 1994 | 1514 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2001 | 4712 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 2001 | 1561 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2011 | 1895 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2131 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5889 | 0.010 |
Why?
|
| Thrombosis | 1 | 1997 | 2957 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2008 | 12800 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 2 | 2001 | 2633 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2013 | 2650 | 0.010 |
Why?
|
| Indoles | 1 | 2011 | 1836 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1988 | 977 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 6231 | 0.010 |
Why?
|
| Complement C5b | 1 | 2001 | 9 | 0.010 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 2001 | 11 | 0.010 |
Why?
|
| Spleen | 1 | 1988 | 2295 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 3814 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1999 | 8128 | 0.010 |
Why?
|
| Complement C5 | 1 | 2001 | 104 | 0.010 |
Why?
|
| Rats | 4 | 1999 | 23760 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 891 | 0.010 |
Why?
|
| Family Planning Services | 1 | 2003 | 279 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 3 | 1999 | 9263 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 8317 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 4352 | 0.010 |
Why?
|
| Natriuresis | 1 | 1999 | 106 | 0.010 |
Why?
|
| Animals | 8 | 2011 | 169246 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2001 | 1065 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 1363 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 13490 | 0.010 |
Why?
|
| Inflammation | 1 | 1999 | 10873 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1159 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 109 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 9561 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1998 | 305 | 0.010 |
Why?
|
| Incidence | 3 | 2003 | 21538 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 106 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5902 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 15662 | 0.010 |
Why?
|
| Mice | 4 | 2011 | 82029 | 0.010 |
Why?
|
| Time Factors | 4 | 2003 | 40218 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1999 | 386 | 0.010 |
Why?
|
| Immunization | 1 | 2001 | 1219 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1550 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2410 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1988 | 5505 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1999 | 611 | 0.010 |
Why?
|
| Growth Substances | 1 | 1998 | 759 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2001 | 1826 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8542 | 0.010 |
Why?
|
| Steroids | 1 | 2001 | 938 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 317 | 0.010 |
Why?
|
| Reperfusion | 1 | 1996 | 266 | 0.010 |
Why?
|
| Iothalamic Acid | 1 | 1994 | 18 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 1599 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 2914 | 0.010 |
Why?
|
| Models, Biological | 1 | 2011 | 9495 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 2560 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 5703 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 2403 | 0.010 |
Why?
|
| Proteinuria | 1 | 1997 | 611 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26379 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1836 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1281 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11669 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 1765 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 1660 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 16045 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 22379 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1994 | 381 | 0.010 |
Why?
|
| Azathioprine | 1 | 1994 | 354 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 60066 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 4938 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1999 | 8543 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 1034 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 1515 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 1996 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 3721 | 0.010 |
Why?
|
| Length of Stay | 1 | 2003 | 6498 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 9374 | 0.010 |
Why?
|
| Prednisone | 1 | 1994 | 1567 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1996 | 4030 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1994 | 2357 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2011 | 23645 | 0.000 |
Why?
|
| Heart Rate | 1 | 1999 | 4214 | 0.000 |
Why?
|
| Reoperation | 1 | 1997 | 4329 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7598 | 0.000 |
Why?
|
| Risk Factors | 2 | 2004 | 74944 | 0.000 |
Why?
|
| Cell Line | 1 | 1998 | 15597 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 10760 | 0.000 |
Why?
|
| Neutrophils | 1 | 1996 | 3786 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 1996 | 14488 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 36535 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2001 | 41754 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2001 | 42669 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 65371 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 13676 | 0.000 |
Why?
|
| Child | 1 | 2001 | 80917 | 0.000 |
Why?
|